logo
Plus   Neg
Share
Email

Regeneron, Zoetis Announce Research Collaboration - Quick Facts

Regeneron Pharmaceuticals, Inc. (REGN) and Zoetis Inc. (ZTS) announced a five-year collaboration to research the use of Regeneron's monoclonal antibody therapeutics in animals and discover new veterinary treatments. Regeneron has granted Zoetis a license for its VelocImmune antibody technology, which Zoetis will use to develop monoclonal antibodies modified for species-specific use in companion and livestock animals.

Regeneron will receive a license fee, approval and sales milestone payments and royalties on any potential veterinary treatments.

For comments and feedback contact: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Luckin Coffee Inc., Starbucks Corp.'s biggest rival in China, filed for an Initial Public Offering in the U.S. In a filing with the Securities and Exchange Commission, the China-based coffee chain said it has applied for listing its American Depositary Shares or ADSs on the Nasdaq under the symbol "LK" and also set a placeholder amount of $100 million. Micro-blogging site Twitter Inc. (TWTR) Tuesday reported a surge in its first-quarter profit. Both earnings and revenues beat analysts' estimates, sending shares up by 6 percent in the pre-market trading. But, Twitter's average monthly active users or MAU figure declined from last year. Verizon Communications Inc. on Tuesday reported a nearly 11 percent increase in profit for the first quarter from last year on higher wireless revenues and flat expenses. Adjusted earnings per share for the quarter beat analysts' estimates, while revenues were in-line with expectations. Looking ahead, the company raised its adjusted earnings outlook for fiscal 2019.
Follow RTT